Page last updated: 2024-12-04

cysteine sulfinic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

3-sulfino-L-alanine : The organosulfinic acid arising from oxidation of the sulfhydryl group of L-cysteine. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

cysteine sulfinic acid: metabolite of sulfur-containing amino acids [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID1549098
CHEMBL ID1160508
CHEBI ID16345
SCHEMBL ID189097
MeSH IDM0061250
PubMed CID109
CHEMBL ID1702607
SCHEMBL ID443654
MeSH IDM0061250

Synonyms (100)

Synonym
CHEBI:16345 ,
(2r)-2-amino-3-sulfinopropanoic acid
BIOMOL-NT_000190
BPBIO1_001212
EU-0100263
tocris-0216
NCGC00024500-01
LOPAC0_000263
1115-65-7
l-cysteinesulfinic acid
3-sulfino-l-alanine
3-SULFINOALANINE ,
3-sulphino-l-alanine
C00606 ,
l-cysteinesulphinic acid
s-sulfinocysteine
DB02153
s-cysteinesulfinic acid
NCGC00024500-04
NCGC00024500-03
NCGC00024500-02
alanine 3-sulfinic acid
cysteine hydrogen sulfite ester
FF909059-FA51-40A0-8973-9E4ECFB8C92A
cysteinesulfinic acid
C 4418
NCGC00024500-05
l-cysteine sulfinic acid
BMSE000706
CHEMBL1160508
HMS3260F08
AKOS006280503
l-alanine, 3-sulfino-
CCG-204358
einecs 214-228-5
56x032nvql ,
cysteinesulfinic acid, l-
unii-56x032nvql
l-2-amino-3-sulfinopropionic acid
alanine, 3-sulfino-, l-
LP00263
l-csa
gtpl5447
l-cysteine sulphinic acid
SCHEMBL189097
tox21_500263
NCGC00260948-01
HB0380
c3h7no4s.h2o
SR-01000597398-1
sr-01000597398
cysteinesulfinic acid, (+)-
cysteinesulfinate, l-
3-sulfino-alanine
SR-01000075758-1
sr-01000075758
3-sulfino- alanine
s-cysteinesulfinic acid; s-sulfinocysteine
DTXSID20862546
Q2823252
HMS3675A19
sulfino-d-alanine
HMS3411A19
SDCCGSBI-0050251.P002
NCGC00387045-02
l-cysteinesulfinic-acid
CS-0020450
MS-22867
HY-100804
(2r)-2-amino-3-[(r)-sulfino]propanoic acid
HMS3266C09
MLS000859909
smr000326770
cysteine sulfinic acid
2381-08-0
2-amino-3-sulfinopropanoic acid
nsc_109
cas_109
bdbm86194
HMS2235M21
alanine, 3-sulfino-
unii-uzy4hyk4zx
uzy4hyk4zx ,
FT-0633338
HMS3369H02
gtpl4695
SCHEMBL443654
AKOS022145786
CHEMBL1702607
J-002599
cysteinesulfinic acid, (dl)-
alaninesulfinic acid
cysteinesulfinate, dl-
cysteinesulfinic acid, (+/-)-
ADVPTQAUNPRNPO-UHFFFAOYSA-N
Q27071879
sulfino-dl-alanine
STL570291
l-cysteinesulfinicacid
DTXSID201336725

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Large (19-fold) increases in cortical cysteine sulphinate concentration were noted after injection of a toxic dose of cysteine."( Cysteine sulphinate and cysteate: mediators of cysteine toxicity in the neonatal rat brain?
Hagberg, H; Lehmann, A; Orwar, O; Sandberg, M, 1993
)
0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (4)

RoleDescription
metabotropic glutamate receptor agonistAn agonist that selectively binds to and activates a metabotropic glutamate receptor.
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
Escherichia coli metaboliteAny bacterial metabolite produced during a metabolic reaction in Escherichia coli.
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
organosulfinic acidOrganic derivatives of sulfinic acid in which the sulfino group is linked directly to carbon.
S-substituted L-cysteine
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (6)

PathwayProteinsCompounds
Methionine and Cysteine metabolism ( Methionine and Cysteine metabolism )2342
2-Oxo-glutaric acid + L-Cysteine-sulfinic acid = L-Glutamic acid + 3-Sulfinyl-pyruvic acid ( Methionine and Cysteine metabolism )24
Trans-sulfuration, one-carbon metabolism and related pathways053
Biochemical pathways: part I0466
One-carbon metabolism and related pathways038
Metabolic Epileptic Disorders2589

Protein Targets (18)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency0.31620.003245.467312,589.2998AID2517
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency35.48130.177814.390939.8107AID2147
dopamine D1 receptorHomo sapiens (human)Potency18.35640.00521.30228.1995AID624455
thioredoxin reductaseRattus norvegicus (Norway rat)Potency18.88760.100020.879379.4328AID588453
phosphopantetheinyl transferaseBacillus subtilisPotency62.05060.141337.9142100.0000AID1490
GLS proteinHomo sapiens (human)Potency3.54810.35487.935539.8107AID624146
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency29.88160.011212.4002100.0000AID1030
regulator of G-protein signaling 4Homo sapiens (human)Potency37.68580.531815.435837.6858AID504845
arylsulfatase AHomo sapiens (human)Potency0.33811.069113.955137.9330AID720538
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency12.35450.035520.977089.1251AID504332
thyroid hormone receptor beta isoform aHomo sapiens (human)Potency31.62280.010039.53711,122.0200AID1479
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency19.01150.060110.745337.9330AID485368
Chain A, JmjC domain-containing histone demethylation protein 3AHomo sapiens (human)Potency35.48130.631035.7641100.0000AID504339
Smad3Homo sapiens (human)Potency6.30960.00527.809829.0929AID588855
apical membrane antigen 1, AMA1Plasmodium falciparum 3D7Potency15.84890.707912.194339.8107AID720542
gemininHomo sapiens (human)Potency1.83560.004611.374133.4983AID624296
Rap guanine nucleotide exchange factor 4Homo sapiens (human)Potency17.78283.981146.7448112.2020AID720708
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (16)

Processvia Protein(s)Taxonomy
asparagine biosynthetic processAsparagine synthetase [glutamine-hydrolyzing]Homo sapiens (human)
asparagine biosynthetic processAsparagine synthetase [glutamine-hydrolyzing]Homo sapiens (human)
glutamine metabolic processAsparagine synthetase [glutamine-hydrolyzing]Homo sapiens (human)
cellular response to glucose starvationAsparagine synthetase [glutamine-hydrolyzing]Homo sapiens (human)
negative regulation of apoptotic processAsparagine synthetase [glutamine-hydrolyzing]Homo sapiens (human)
positive regulation of mitotic cell cycleAsparagine synthetase [glutamine-hydrolyzing]Homo sapiens (human)
L-asparagine biosynthetic processAsparagine synthetase [glutamine-hydrolyzing]Homo sapiens (human)
adaptive immune responseRap guanine nucleotide exchange factor 4Homo sapiens (human)
G protein-coupled receptor signaling pathwayRap guanine nucleotide exchange factor 4Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayRap guanine nucleotide exchange factor 4Homo sapiens (human)
calcium-ion regulated exocytosisRap guanine nucleotide exchange factor 4Homo sapiens (human)
regulation of exocytosisRap guanine nucleotide exchange factor 4Homo sapiens (human)
insulin secretionRap guanine nucleotide exchange factor 4Homo sapiens (human)
positive regulation of insulin secretionRap guanine nucleotide exchange factor 4Homo sapiens (human)
regulation of synaptic vesicle cycleRap guanine nucleotide exchange factor 4Homo sapiens (human)
Ras protein signal transductionRap guanine nucleotide exchange factor 4Homo sapiens (human)
regulation of insulin secretionRap guanine nucleotide exchange factor 4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (7)

Processvia Protein(s)Taxonomy
asparagine synthase (glutamine-hydrolyzing) activityAsparagine synthetase [glutamine-hydrolyzing]Homo sapiens (human)
protein bindingAsparagine synthetase [glutamine-hydrolyzing]Homo sapiens (human)
ATP bindingAsparagine synthetase [glutamine-hydrolyzing]Homo sapiens (human)
guanyl-nucleotide exchange factor activityRap guanine nucleotide exchange factor 4Homo sapiens (human)
protein bindingRap guanine nucleotide exchange factor 4Homo sapiens (human)
cAMP bindingRap guanine nucleotide exchange factor 4Homo sapiens (human)
protein-macromolecule adaptor activityRap guanine nucleotide exchange factor 4Homo sapiens (human)
small GTPase bindingRap guanine nucleotide exchange factor 4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (4)

Processvia Protein(s)Taxonomy
cytosolAsparagine synthetase [glutamine-hydrolyzing]Homo sapiens (human)
cytosolAsparagine synthetase [glutamine-hydrolyzing]Homo sapiens (human)
cytosolRap guanine nucleotide exchange factor 4Homo sapiens (human)
plasma membraneRap guanine nucleotide exchange factor 4Homo sapiens (human)
membraneRap guanine nucleotide exchange factor 4Homo sapiens (human)
hippocampal mossy fiber to CA3 synapseRap guanine nucleotide exchange factor 4Homo sapiens (human)
plasma membraneRap guanine nucleotide exchange factor 4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (37)

Assay IDTitleYearJournalArticle
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID39244Competitive Inhibition constant of Asparagine synthetase of Glutamine-Dependent Synthetase Activity using aspartate as substrate; na = 'not applicable'1996Journal of medicinal chemistry, Jun-07, Volume: 39, Issue:12
Mapping the aspartic acid binding site of Escherichia coli asparagine synthetase B using substrate analogs.
AID39250Competitive Inhibition constant of Asparagine synthetase of Glutamine-Dependent Synthetase Activity using aspartate as substrate1996Journal of medicinal chemistry, Jun-07, Volume: 39, Issue:12
Mapping the aspartic acid binding site of Escherichia coli asparagine synthetase B using substrate analogs.
AID328866Binding affinity to Pyrococcus horikoshii sodium-coupled aspartate transporter2007Nature, Jan-25, Volume: 445, Issue:7126
Coupling substrate and ion binding to extracellular gate of a sodium-dependent aspartate transporter.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1745845Primary qHTS for Inhibitors of ATXN expression
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (257)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990100 (38.91)18.7374
1990's53 (20.62)18.2507
2000's54 (21.01)29.6817
2010's42 (16.34)24.3611
2020's8 (3.11)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 34.38

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index34.38 (24.57)
Research Supply Index5.50 (2.92)
Research Growth Index4.32 (4.65)
Search Engine Demand Index47.50 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (34.38)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials1 (0.41%)5.53%
Reviews0 (0.00%)6.00%
Reviews11 (4.53%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies1 (0.41%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other16 (100.00%)84.16%
Other230 (94.65%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]